C17orf100

Across TCGA pan-cancer cohorts, C17orf100 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of C17orf100’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where C17orf100 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types C17orf100 is over-expressed in tumor, although a few such as KICH and BRCA show the opposite, repressed pattern.

BLCA, KICH, and LUSC are the cancer types where C17orf100 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in C17orf100 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	All	+0.851	<.001	8	view →
KICH	Female	All	−1.297	<.001	7	view →
LUSC	Male	II,III,IV	+0.866	<.001	6	view →
LUAD	All	All	+0.400	<.001	6	view →
KIRP	All	All	+0.582	.002	5	view →
BRCA	Female	All	−0.364	<.001	4	view →
COAD	Male	III,IV	+0.941	.018	3	view →
CHOL	Male	All	+1.148	.002	2	view →
HNSC	Male	III,IV	+0.716	.019	2	view →
ESCA	All	All	+0.728	.039	1	view →
KIRC	Male	All	+0.185	.044	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

C17orf100–BLCA

Open the BLCA breakdown →